CoChat
Sign Up
Cited by 182Systemic Lupus Erythematosus ResearchReproductive System and PregnancyPregnancy and preeclampsia studies

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study

Mekinian, Arsène, Lazzaroni, Maria Grazia, Kuzenko, Anna, Alijotas-Reig, Jaume, Ruffatti, Amelia, Levy, Pierre, Canti, Valentina, Bremme, Katarina, Bezanahary, Holy, Bertero, Tiziana, Dhote, Robin, Maurier, Francois, Andreoli, Laura, Benbara, Amélie, Tigazin, Ahmed, Carbillon, Lionel, Nicaise-Roland, Pascale, Tincani, Angela, Fain, Olivier·2015·Autoimmunity Reviews
DOI 10.1016/j.autrev.2015.01.012
Open this paper in CoChat — free account

Abstract

In European multicenter study, we aimed to describe the real-life hydroxychloroquine use in APS patients during pregnancy and determine its benefit in refractory obstetrical APS. We analyzed the outcome of pregnancies treated by hydroxychloroquine in patients with APS or asymptomatic antiphospholipid (aPL) antibodies carriers. Thirty patients with APS with 35 pregnancies treated by hydroxychloroquine were analyzed. Comparing the outcome of pregnancies treated by the addition of hydroxychloroquine to previous pregnancies under the conventional treatment, pregnancy losses decreased from 81% to 19% (p<0.05), without differences in the associated treatments. The univariate analysis showed that the previous intrauterine deaths and higher hydroxychloroquine amount (400mg per day) were the factors associated with pregnancy outcome. Considering 14 patients with previous refractory obstetrical APS (n=5 with obstetrical and thrombotic primary APS and n=9 with purely obstetrical APS), all with previous pregnancy losses under treatment (aspirin with LMWH in 11 cases and LMWH in 3 cases), the addition of hydroxychloroquine resulted in live born babies in 11/14 (78%) cases (p<0.05). Our study shows the benefit of hydroxychloroquine addition in patients with refractory obstetrical APS and raises the need of prospective studies to confirm our preliminary study.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.autrev.2015.01.012

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

See all 182

Related

See all

Metadata

Authors
Mekinian, A., Lazzaroni, M. G., Kuzenko, A., Alijotas-Reig, J., Ruffatti, A., Levy, P., Canti, V., Bremme, K., Bezanahary, H., Bertero, T., Dhote, R., Maurier, F., Andreoli, L., Benbara, A., Tigazin, A., Carbillon, L., Nicaise-Roland, P., Tincani, A., & Fain, O.
Affiliations
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
  • A. O. Ordine Mauriziano di Torino (IT)
  • University of Padua (IT)
  • IRCCS Ospedale San Raffaele (IT)
  • Karolinska Institutet (SE)
  • Université Sorbonne Paris Nord (FR)
ORCID
Venue
Autoimmunity Reviews
Publisher
Elsevier BV
Published
2015-06
Volume
14
Issue
6
Pages
498-502
ISSN
1568-9972 (ISSN-L)
DOI
10.1016/j.autrev.2015.01.012
OpenAlex
W1966792319
Cited by
182
References
22
Citations by year
2026: 7 · 2025: 11 · 2024: 13 · 2023: 8 · 2022: 16 · 2021: 14 · 2020: 23 · 2019: 21 · 2018: 24 · 2017: 14 · 2016: 20 · 2015: 11
FWCI
19.30
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Autoimmunity Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
Keywords
hydroxychloroquine, antiphospholipid syndrome, pregnancy outcomes, miscarriage, antiphospholipid antibodies, low molecular weight heparin, aspirin, live birth, intrauterine fetal death
MeSH terms
Female, Humans, Hydroxychloroquine, Pregnancy, Pregnancy Outcome, Retrospective Studies, Multicenter Studies as Topic, Antiphospholipid Syndrome, Antibodies, Antiphospholipid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review